Company intelligence / Profile preview
SCHISM Bioworks
Florida, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SCHISM Bioworks commercializes the novel probiotic P.UF1 (Propionibacterium freudenreichii P.UF1), shown in preclinical studies to protect against intestinal inflammation, support immune homeostasis, and produce significant levels of vitamin B12 and other beneficial metabolites. Its first commercial product launched in partnership with Gundry MD. The strain is pending GRAS status and Health Canada NPN approval.
- Therapeutic areas
- GastroenterologyInfectious DiseasesImmunology
- Modalities
- Live biotherapeutic product therapyProbiotic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gundry MDIncrenovo (Dr. Ralf Jäger, scientific advisor)
Beyond the preview
Go deeper on SCHISM Bioworks.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCHISM Bioworks.